▎CapstanEdited by Kant Content Team
Capstan Therapeutics Announces Successful Completion of $175 Million Oversubscribed Series B FinancingCapstan Therapeutics today announced the successful completion of a $175 million oversubscribed Series B financing. This round was led by RA Capital Management, with new investors including Forbion, Johnson & Johnson Innovation (JJDC), Mubadala Capital, Perceptive Advisors, and Sofinnova Investments, among others. Existing investors in Capstan, such as Alexandria Venture Investments, Bristol-Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures, also participated in this financing.
The funds raised from Series B financing will be used to advance Capstan’s lead in vivo chimeric antigen receptor T-cell (CAR-T) candidate therapy, CPTX2309, in early clinical proof-of-concept for autoimmune diseases, and to further develop Capstan’s targeted lipid nanoparticle (tLNP) pipeline.CPTX2309 is a product of Capstan Therapeutics' tLNP platform, which delivers mRNA payloads encoding chimeric antigen receptors targeting CD19 to CD8-expressing T cells, effectively generating CAR-T cell therapy directly in vivo.The goal of this approach is to reset the immune system by rapidly and deeply depleting B cells in the blood and lymphoid tissues, while avoiding the challenges associated with traditional ex vivo production of CAR-T cell therapy.Dr. Laura Shawver is the President and Chief Executive Officer of Capstan Therapeutics. She previously served as the Chief Executive Officer of Silverback Therapeutics and as the President and Chief Executive Officer of Synthorx, bringing over 20 years of experience in executive leadership roles. She is also the founder and director of The Clearity Foundation, a non-profit organization dedicated to improving treatment options for ovarian cancer patients.▲Dr. Laura Shawver Shares Insights on Gene and Cell Therapy Development at the 2023 WuXi AppTec Global Forum
In2023 Wuxi AppTec Global ForumAbove, Dr. Shawver stated that in the field of gene therapy, the industry has recognized the limitations of viral vectors. Therefore, non-viral vectors, including LNPs, will have a place in the future development of gene therapies.For LNP vector technology, the challenge lies in how to specifically deliver LNPs to different types of cells. Capstan Therapeutics' tLNP technology platform, by decorating LNPs with antibodies or antibody fragments that bind to specific receptors, is expected to solve the problem of targeted delivery.As a CTDMO under WuXi AppTec that focuses on cell and gene therapies, WuXi Advanced Therapies is committed to accelerating and transforming the development, testing, manufacturing, and commercialization of gene and cell therapies as well as other advanced therapies. WuXi Advanced Therapies can help global customers bring more innovative treatments to market sooner, benefiting patients. If you have related business needs, please click on the image below to fill in the specific information.▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接 platform and fill in your business needs information.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
References:
[1] Capstan Therapeutics Announces $175M Oversubscribed Series B Financing. Retrieved March 20, 2024, from https://www.businesswire.com/news/home/20240320334454/en/Capstan-Therapeutics-Announces-175M-Oversubscribed-Series-B-Financing
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.
Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In View，Focusing on Global Biomedical Health Innovation
